HDAC inhibitors-based antibody drug conjugates (ADCs) and use in therapy

The present invention relates to novel Histone Deacetylase Inhibitors (HDACi)- based antibody drug conjugates particularly with antibodies directed to ErbB1, ErbB2 and ErbB3 receptors, pharmaceuticalcompositions comprising the antibodies as well as to their use in the treatment of cancer or tumor and other diseases where a modulation of one or more histone deacetylase isoforms can be effective for therapeutic interventions. 本发明涉及新的基于组蛋白脱乙酰基酶抑制剂(HDACi)的抗体药物缀合物，特别是与针对ErbB1、ErbB2、ErbB3受体的抗体缀合的抗体药物缀合物，涉及包含所述抗体的药物组合物，以及它们在治疗癌症或肿瘤以及其中调节一种或多种组蛋白脱乙酰基酶同种型可以有效用于治疗干预的其他疾病中的用途。